Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

Full description

Saved in:
Bibliographic Details
Published in:Clin Kidney J
Main Authors: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
CKD-Mdb
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://ncbi.nlm.nih.gov/pubmed/32082556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz034
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items